The journal of allergy and clinical immunology. Global · 2026
Prevalence and features of eosinophilic gastrointestinal disorders using the large real-world TriNetX database.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miracle Cora E, Zevit Noam, Gerster Edward, Kliewer Kara, Rothenberg Marc E
Аннотация
BACKGROUND: There are substantial questions concerning the epidemiology and demographics of eosinophilic gastrointestinal disorders (EGID). We queried TriNetX, a large electronic medical record database, to assess EGID demographics.
OBJECTIVES: Our objective for this study was to characterize the prevalence, demographic features, disease overlap, and treatment patterns of patients with EGID using a large multicenter electronic health record database.
METHODS: TriNetX, a deidentified patient database derived from 92 health care organizations and a total population of 129,260,452 patients, was queried for EGID. Cases were identified by ICD codes (eosinophilic esophagitis [EoE] K20, eosinophilic gastritis/enteritis [EoG/EoN] K52.81, eosinophilic colitis [EoC] K52.82) and endoscopy occurrence. Demographic and clinical characteristics were analyzed.
RESULTS: We identified 77,726 EoE, 6,554 EoG/EoN, and 2,898 EoC cases. Prevalence was approximately 1:1,673, 1:19,842, and 1:44,873, respectively. Multiple EGID occurred in 5% of all patients but in 47% of those with EoG/EoN. EGID was most common in non-Hispanic White individuals (79%). Male predominance was observed in EoE (59%) but not EoG/EoN (46%) or EoC (45%). Mean patient ages at query were 39, 31, and 40 years for EoE, EoG/EoN, and EoC, respectively (P < .0001). The most prescribed medications were proton pump inhibitors for EoE, antiemetics and corticosteroids for EoG/EoN, and corticosteroids for EoC.
CONCLUSIONS: We identified the largest reported population of patients with EGID (77,726 cases); our findings substantiate their rarity (0.002-0.5% prevalence), male predominance limited to EoE, substantial co-occurrence of multiple EGID, and distinct age distribution of EoG/EoN. The identified cohort and approaches provide opportunities for further research.
OBJECTIVES: Our objective for this study was to characterize the prevalence, demographic features, disease overlap, and treatment patterns of patients with EGID using a large multicenter electronic health record database.
METHODS: TriNetX, a deidentified patient database derived from 92 health care organizations and a total population of 129,260,452 patients, was queried for EGID. Cases were identified by ICD codes (eosinophilic esophagitis [EoE] K20, eosinophilic gastritis/enteritis [EoG/EoN] K52.81, eosinophilic colitis [EoC] K52.82) and endoscopy occurrence. Demographic and clinical characteristics were analyzed.
RESULTS: We identified 77,726 EoE, 6,554 EoG/EoN, and 2,898 EoC cases. Prevalence was approximately 1:1,673, 1:19,842, and 1:44,873, respectively. Multiple EGID occurred in 5% of all patients but in 47% of those with EoG/EoN. EGID was most common in non-Hispanic White individuals (79%). Male predominance was observed in EoE (59%) but not EoG/EoN (46%) or EoC (45%). Mean patient ages at query were 39, 31, and 40 years for EoE, EoG/EoN, and EoC, respectively (P < .0001). The most prescribed medications were proton pump inhibitors for EoE, antiemetics and corticosteroids for EoG/EoN, and corticosteroids for EoC.
CONCLUSIONS: We identified the largest reported population of patients with EGID (77,726 cases); our findings substantiate their rarity (0.002-0.5% prevalence), male predominance limited to EoE, substantial co-occurrence of multiple EGID, and distinct age distribution of EoG/EoN. The identified cohort and approaches provide opportunities for further research.